Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Leukemia 46Lymphoma 12Burkitt Lymphoma 7Leukemia, Promyelocytic, Acute 6Neoplasm, Residual 5Leukemia, Biphenotypic, Acute 5Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Dendritic Cell Sarcoma, Interdigitating 2Thrombocytopenia 1Rare Diseases 1Psoriasis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Ovarian Neoplasms 1Oligodendroglioma 1Neutropenia 1Neoplasms 1Mucositis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1

Interventions

Melphalan 3sargramostim 1romidepsin 1montanide ISA 51 1keyhole-limpet hemocyanin 1detox adjuvant 1Ursodeoxycholic Acid 1Thalidomide 1Streptozocin 1Mercaptopurine 1Leucovorin 1Interleukin-2 1Floxuridine 1FANG vaccine 1Docetaxel 1Celecoxib 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Genetic Diseases, Inborn × Mercaptopurine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡